Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography
Locations
Other Locations
Egypt
Tanta Unuversity
RECRUITING
Tanta
Time Frame
Start Date: 2025-03-01
Estimated Completion Date: 2026-04-20
Participants
Target number of participants: 46
Treatments
Active_comparator: Control group
Patients will receive the standard conventional therapy in addition to placebo for 3 months.
Active_comparator: Carbocistiene group
Patients will be given the standard conventional therapy plus carbocistiene 375 mg two times daily.
Related Therapeutic Areas
Sponsors
Leads: Tanta University